A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs TF 0023 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Sponsors Techfields Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top